





FIG. 1





BINDING INHIBITION

















FIG.5B




FIG.5C

INTERLEUKINE-2 RECEPTOR




FIG. 6A

IL-2 AND IP 130 SEQUENCE (α -HELICES ARE BOXED)









FIG. 6B






















FIG. 9E





■ IL-2 + mAb A41

□ IL-9 + mAb A41






FIG. 9D

ACTIVITY	‡	+ +	I	ı	ı	Q	+	
MAIN MOLECULAR SPECIES	ETRAMER (4M-8M, Kd=30-100 μ M) /OCTAMER	DIMER (1M-2M,Kd=0,2μM) /TETRAMER (2M-4M,Kd=100μM)		(1M-2M,Kd=50µM) (2M-4M,Kd=1,4mM)	(1M-2M,Kd=113µM)	ER	H	
MAIN M	TETRAMER (DIMER /tetra		DIMER	DIMER	MONOMER	MONOMER	10
% HELIX (CIRCULAR DICHROISM)	50% (150 @ 30µM) 35% (4µM)	22% (150 @ 30µM)	<2%	%0	%0	%0	~5%	FIG. 10
1 10 20 30 APTTSSSTKKTQLQLEHLLLDLQMILNGINN	1 30	10 30	1 22	1 10	5 15	10 20	20 20	



IP130


FIG. 11A




IP130

FIG. 11B

BLOT 4G10 (ANTI PHOSPHOTYROSINE)







ACTIVATED STATS

NO STIMULATION

1-2

1-2

1-2

1-2

1-3




FIG. 14

NK CELLS (CD56 $^+$) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION (SYNERGY WITH IL-2)

TREAT	MEN	Γ		J31	J32	J33
IL-2 50 nM				14	12	14
		IP130	60 <i>µ</i> М	0	17	≤ 5
		IP130	120µM	0	14	< 5
IL-2 50 nM	+	IP130	60 μΜ	26	21	7
IL-2 50 nM	+	IP130	120 <i>µ</i> M	28	28	28

FIG. 15





FIG. 16B







FIG. 16D






FIG. 16F




FIGURE 17




FIGURE 18




FIGURE 19